《“30MO ORIENT-3：一项关于信迪利单抗与多西他赛在既往治疗的晚期/转移性鳞状非小细胞肺癌（sqNSCLC）中的随机、开放标签、III期研究”撤稿声明》：[《肿瘤学年鉴》第31卷，增刊7，2020年12月，第S1428页]
Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428].
作者信息
Shi Y, Wu L, Yu X, Xing P, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y
机构信息
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department II of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China.
出版信息
Ann Oncol. 2021 Apr;32(4):576. doi: 10.1016/j.annonc.2021.01.009.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article was retracted at the request of the authors. The authors of this abstract have advised that full agreement between authors and sponsors on publication of the abstract has not been reached and they are therefore unable to publish this data at present.
Zotero 插件